Corrigendum Of February 16, 2015 V&a # 280 Determines On The Marketing Authorisation For Product For Human Use "humulin".

Original Language Title: Rettifica della determina V&A n. 280 del 16 febbraio 2015,concernente l'autorizzazione all'immissione in commercio delmedicinale per uso umano «Humulin».

Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-04-20&atto.codiceRedazionale=15A02815&elenco30giorni=false&atto.tipoProvvedimento=DECRETO

Retrieved 1 April # 614 V&A determines the 2015 it is corrected, in the following terms, the extract of determination V&A # 280 of February 16, 2015 concerning the marketing authorisation for the medicinal product HUMULIN, whose retrieved it was published in the official journal-General series No 55 of March 7, 2015: where it is: ' let there be lots already products on the date of entry into force of this determination that the batches produced during the period referred to in article 2, paragraph 1, of this , not bearing approved changes can be kept on the market until the expiration date printed on the label of the medicine. Pharmacists are required to deliver the package leaflet updated users, as from the end of 30 days from the date of publication in the Official Gazette of the Italian Republic of this determination. The Mah makes accessible to pharmacist leaflet updated within the same timeframe. ';
read: "Let there be lots already products on the date of entry into force of this determination that the batches produced during the period referred to in article 2, paragraph 1, of the present, not bearing approved changes can be kept on the market until the expiration date printed on the label of the medicinal product. ';
A.I.C. Owner: ELI LILLY ITALIA S.P.A. (tax 00426150488) with registered office and tax domicile in Via Gramsci, 731/733-50019 Sesto Fiorentino-Florence (FI) Italy.
Final provisions this excerpt will be published in the official journal of the Italian Republic, while its determination will be notified to the company holder of the marketing authorisation of the medicinal product.